ArticlePloS one2026
Ligustroside attenuates fibrosis-associated wound remodeling and suppresses fibrosis-related signaling in a rat excisional wound model.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis-associated wound remodeling is a feature of cutaneous wound healing characterized by fibroblast activation, extracellular matrix deposition, and profibrotic signaling. Ligustroside, a major iridoid glycoside derived from Ligustrum lucidum, has demonstrated antifibrotic activity in several organ systems, but its effects on cutaneous wound remodeling remain unclear. In this study, a full-thickness excisional wound model was established in female Sprague-Dawley rats to investigate the effects of ligustroside on fibrosis-associated wound remodeling. Animals received ligustroside (5 or 10 mg/kg) or vehicle control. Wound formation was evaluated using the Vancouver Scar Scale, histopathological staining, and analysis of fibrosis-related markers. Ligustroside treatment significantly reduced wound severity during the remodeling phase and improved dermal architecture, as evidenced by decreased dermal thickening, reduced inflammatory infiltration, and more organized collagen fibers. Molecular analyses showed that ligustroside markedly downregulated α-smooth muscle actin and transforming growth factor-β1 expression, accompanied by showing a dose-responsive trend within the tested dose range. These findings indicate that ligustroside attenuates fibrosis-associated wound remodeling and suppresses fibrosis-related molecular responses, including TGF-β1 expression, myofibroblast activation, and extracellular matrix accumulation. Collectively, these results suggest that ligustroside may represent a promising plant-derived candidate for antifibrotic wound modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.